Mijiao formula regulates NAT10-mediated Runx2 mRNA ac4C modification to promote bone marrow mesenchymal stem cell osteogenic differentiation and improve osteoporosis in ovariectomized rats

• Published in: Journal of ethnopharmacology 2024-08, Vol.330, p.118191-118191, Article 118191
• Main Authors: Xiao, Dong, Huang, Sirui, Tang, Zhuqian, Liu, Mengqiu, Di, Di, Ma, Yingrun, Li, Yunjuan, Duan, Jin-Ao, Lu, Cai, Zhao, Ming
• Format: Article
• Language: English
• Subjects: Animals; Cell Differentiation - drug effects; Cells, Cultured; Core Binding Factor Alpha 1 Subunit - genetics; Core Binding Factor Alpha 1 Subunit - metabolism; Disease Models, Animal; Drugs, Chinese Herbal - pharmacology; Female; Mesenchymal Stem Cells - drug effects; Mijiao formula; NAT10; Osteogenesis - drug effects; Osteoporosis; Osteoporosis - drug therapy; Ovariectomy; Rats; Rats, Sprague-Dawley; RNA, Messenger - metabolism; Runx2
• ISSN: 0378-8741; 1872-7573
• DOI: 10.1016/j.jep.2024.118191

The Mijiao (MJ) formula, a traditional herbal remedy, incorporates antlers as its primary constituent. It can effectively treat osteoporosis (OP), anti-aging, enhance immune activity, and change depression-like behavior. In this study, we investigated that MJ formula is a comprehensive treatment strategy, and may provide a potential approach for the clinical treatment of postmenopausal osteoporosis. The purpose of this study was to determine whether MJ formula promoted osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and improved osteoporosis in ovariectomized rats by regulating the NAT10-mediated Runx2 mRNA ac4C modification. Female Sprague-Dawley (SD) rats were used to investigate the potential therapeutic effect of MJ formula on OP by creating an ovariectomized (OVX) rat model. The expression of osteogenic differentiation related proteins in BMSCs was detected in vivo, indicating their role in promoting bone formation. In addition, the potential mechanism of its bone protective effect was explored via in vitro experiments. Our study showed that MJ formula significantly mitigated bone mass loss in the OVX rat model, highlighting its potential as an OP therapeutic agent. We found that the possible mechanism of action was the ability of this formulation to stabilize Runx2 mRNA through NAT10-mediated ac4C acetylation, which promoted osteogenic differentiation of BMSCs and contributed to the enhancement of bone formation. MJ formula can treat estrogen deficiency OP by stabilizing Runx2 mRNA, promoting osteogenic differentiation and protecting bone mass. Conceivably, MJ formulation could be a safe and promising strategy for the treatment of osteoporosis. [Display omitted]